SEMA4D Blockade and HTT-Lowering Combination Therapy for Huntington's Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Huntington's disease (HD) do not alter the course of the disease, and there is a need for effective therapies that can alleviate symptoms such as movement and psychiatric issues.
Innovation Solution
A combination therapy involving a binding molecule that specifically binds to semaphorin-4D (SEMA4D) and an HTT-lowering agent, such as an antisense oligonucleotide, to inhibit SEMA4D interactions and reduce huntingtin protein levels, thereby enhancing therapeutic efficacy in treating HD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If HTT-lowering therapy is used alone, then huntingtin protein levels are reduced, but therapeutic efficacy is insufficient to fully address HD symptoms
Solution Approach 1:
The patent combines HTT-lowering therapy with SEMA4D blockade therapy into a single treatment regimen. The antibody against SEMA4D is administered concurrently with or sequentially to the HTT-lowering agent, creating a synergistic effect that addresses both the underlying genetic cause and the downstream pathological mechanisms, thereby improving overall therapeutic efficacy beyond what either treatment could achieve alone.
Solution Approach 2:
The treatment uses a composite therapeutic approach combining two different mechanisms of action: (1) HTT-lowering agents that reduce the quantity of mutant huntingtin protein through RNA interference or antisense oligonucleotides, and (2) SEMA4D-blocking antibodies that inhibit abnormal signaling pathways. This composite strategy targets multiple aspects of HD pathophysiology simultaneously.
2Reliability
If SEMA4D blockade is used alone, then neuropsychiatric and cognitive symptoms improve, but motor dysfunction and brain atrophy are not fully addressed
Solution Approach 1:
The patent integrates SEMA4D blockade therapy with HTT-lowering therapy to create a comprehensive treatment that addresses both symptomatic management and disease-modifying effects. The SEMA4D antibody component provides rapid symptomatic relief for neuropsychiatric and cognitive issues, while the HTT-lowering component progressively reduces mutant protein levels to address motor dysfunction and prevent brain atrophy.
3Reliability
If combination therapy is used, then therapeutic efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent employs an antibody as a mediator that blocks SEMA4D interactions with its receptors. This antibody serves as a soluble blocking molecule that can be administered systemically and provides a mechanism to inhibit abnormal SEMA4D signaling without requiring direct manipulation of neuronal circuits or complex delivery systems, thereby simplifying the combination therapy approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination therapy improves neuropsychiatric symptoms, cognitive functions, motor dysfunction, and brain atrophy, demonstrating enhanced therapeutic benefits compared to single-agent treatments.
Implementation Method 1
a binding molecule that specifically binds to semaphorin-4D (SEMA4D)... the antibody or antigen-binding fragment component of the combination therapy inhibits SEMA4D interactions with its receptor
Implementation Method 2
an HTT-lowering agent, such as an antisense oligonucleotide... to reduce huntingtin protein levels
Data Source
AI summary
Disclosed are combination therapies and methods for the treatment of Huntington's disease comprising the administration of a combination of a SEMA4D binding molecule and an HTT-lowering agent.